Larotrectinib

TargetMol
Product Code: TAR-T5995
Supplier: TargetMol
CodeSizePrice
TAR-T5995-2mg2mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5995-5mg5mg£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5995-1mL1 mL * 10 mM (in DMSO)£133.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5995-10mg10mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5995-50mg50mg£283.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5995-100mg100mg£389.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Larotrectinib is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors(IC50s = 2-20 nM).
CAS:
1223403-58-4
Formula:
C21H22F2N6O2
Molecular Weight:
428.444
Pathway:
Apoptosis; Tyrosine Kinase/Adaptors
Purity:
1
SMILES:
O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F
Target:
Apoptosis; Trk receptor

References

Doebele R C , Davis L E , Vaishnavi A , et al. An oncogenic NTRK fusion in a soft tissue sarcoma patient with response to the tropomyosin-related kinase (TRK) inhibitor LOXO-101[J]. Cancer Discovery, 2015, 5(10):1049-1057. Laetsch T W , Dubois S G , Mascarenhas L , et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study[J]. The Lancet Oncology, 2018:S1470204518301190.